PARP Inhibitors in Melanoma—An Expanding Therapeutic Option?
Wei Yen Chan(Melanoma Institute Australia), Anthony M. Joshua(St Vincent's Hospital Sydney), Lauren Brown(Garvan Institute of Medical Research), Lee B. Reid(UNSW Sydney)
Cited by 28
Related Papers
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
|New England Journal of Medicine|2014|3k
Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma
|New England Journal of Medicine|2021|869
Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer
|Journal of Clinical Oncology|2023|317